<5616> Rain, Wind, Sun 1099 -112

Significant decline. The Tokyo Stock Exchange announced on the 6th that the initial margin requirement for margin trading of the company's stock would be set at 50% or higher (including cash 20% or more), causing a strong selling pressure. Additionally, Japan Securities Finance implemented increased collateral collection measures, setting the collateral requirement for individual net settlement participants and non-net settlement participants at 50% (including 20% cash collateral) from the same day onwards.

<6550> Unipos 178 +50

Hitting the daily price limit, it was announced that the company has started offering specialized culture transformation services focusing on organizational changes before and after business succession, known as 'Culture Transformation for Successors,' which has been well received by buyers. Based on the expertise cultivated through support for more than 370 organizations, the service aims to address the unique concerns and needs during business succession, and concretely promote cultural transformation before and after succession by providing a set of venues, expertise, systems, and content.

<4014> Bodynote 730 +97

Temporarily hitting the daily price limit and reaching a year-to-date high. Today, it was announced that Medley has started collaborating with one of Japan's largest medical care job sites, 'JobMedley,' to promote the active participation of potential nurses and caregivers. This news is viewed positively. The company believes that its life event data and matching expertise contribute to promoting the active participation of potential talent in the medical healthcare field. Hence, they have collaborated with Medley, which currently provides over 450,000 job postings in the medical healthcare field (as of September 2024).

<4890> Tsubota Lab 502 +80

Hitting the daily price limit. It was announced that a patent licensing agreement has been signed with Shenyang Xingqi Pharmaceutical Co., Ltd., a major ophthalmology pharmaceutical manufacturer in China, granting exclusive implementation rights for specific patents in specific regions. 'Xingqi' is a leading pharmaceutical manufacturer specializing in the research, development, manufacturing, and sales of ophthalmic pharmaceuticals in China. The total contract amount is $18 million USD (approximately ¥2.68 billion Japanese Yen). Through this agreement, treatment methods based on the company's patents will be implemented in China.

The purpose is to widely provide treatment methods based on the company's patents in China.

<4586> Medorek 97 -4

Continued decline. It has been announced that the patent assessment for the "Stacked Patch Adhesive" under application after the close of trading on the 5th has been notified by the Patent Office. The patent relates to the structure of the patch adhesive and involves a technology that achieves functional improvement such as adhesive properties improvement by deliberately creating a certain space, and is used in the spastic paralysis treatment drug MRX-4TZT (Tizanidine patch). The patent is valid until 2040, and efforts are being made to obtain rights in the USA, Europe, and China.

<4592> Sanbio 938 -33

Continued decline. After the close of trading on the 5th, it was announced that the analysis results of the Phase 2 STEMTRA trial of the main development product SB623 were published in the Neurology Journal. The analysis evaluated the effectiveness and safety of the main development product SB623 for patients with chronic motor function disorders resulting from traumatic brain injury over 48 weeks in the Phase 2 multi-center double-blind comparison trial with a sham surgery control group (STEMTRA trial) conducted from 2016 to 2019.